EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links


[À§¾Ï 103 - Amphicrine tumor]

Previous | Next

001 | 101 | 201 | 301 | 401 | 501 | 601 | 701 | 801 | 901 | 1000


1. Amphicrine tumor¶õ ¹«¾ùÀΰ¡?

°£È¤ À§¼±¾Ï¿¡ ½Å°æ³»ºÐºñ¼¼Æ÷(neuroendocrine cell)ÀÌ »êÀçµÈ °æ¿ì°¡ ÀÖ´Ù´Â °ÍÀº Àß ¾Ë·ÁÁø »ç½ÇÀÔ´Ï´Ù. ±×·¯³ª endocrine tumor¿Í non-endocrine tumor°¡ ÇÔ²² ¼¯ÀÎ °æ¿ì¿¡ ´ëÇؼ­´Â ¾à°£ÀÇ È¥¼±ÀÌ ÀÖ½À´Ï´Ù. Amphicrine tumor´Â ÇÑ ¼¼Æ÷¿¡¼­ dual epithelial and neuroendocrine differentiationÀÌ ÀϾ Á¾¾çÀÔ´Ï´Ù. Áúº´ ÀÚü´Â aggressiveÇÕ´Ï´Ù. ¹Ý¸é composite tumorÀÇ ¿¹ÈÄ´Â ÁÁ½À´Ï´Ù. .

2005³â Fujiyoshi´Â mixed endocrine and non-endocrine epithelial tumor¸¦ ¾Æ·¡¿Í °°ÀÌ ºÐ·ùÇÏ¿´°í amphicrine tumor´Â ±× Áß ÇϳªÀÔ´Ï´Ù.

  1. neuroendocrine cells interspersed with carcinomas
  2. carcinoids with interspersed non-endocrine cells
  3. composite glandular-neuroendocrine cell carcinomas containing both areas of carcinoid and conventional carcinoma
  4. collision tumors in which neuroendocrine tumors and conventional carcinomas are closely juxtaposed, but not admixed
  5. amphicrine tumors prodominantly composed of cells exhibiting concurrent neuroendocrine and non-endocrine differentiation
  6. combinations of the previous types

@ Images in Pathology - Amphicrine Gastric Carcinoma (Arch Pathol Lab Med. 2001)


ÃÖ±Ù¿¡´Â Mixed Adenoneuroendocrine Carcinomas (MANECs)¶ó´Â À̸§À¸·Î ÅëÀϵǰí ÀÖ´Â °Í °°½À´Ï´Ù (Cancers 2012;4:11-30).


êÖ amphicrine tumor¿Í ºñ½ÁÇÑ °ÍÀÌ appendixÀÇ goblet cell carcinoidÀÔ´Ï´Ù. Goblet cell carcinoid tumors of the appendix: An overview"¶ó´Â 2010³â Á¾¼³À» ¼Ò°³ÇÕ´Ï´Ù. ¿ä¾àÀÇ ÀϺθ¦ ¿Å±é´Ï´Ù. AppendixÀÇ À̾߱âÀε¥ À§µµ ºñ½ÁÇÕ´Ï´Ù.

The tumor is thought to arise from pluripotent intestinal epithelial crypt-base stem cells by dual neuroendocrine and mucinous differentiation. GCCs present in the fifth to sixth decade and show no definite sex predominance. The most common clinical presentation is acute appendicitis, followed by abdominal pain and a mass. Fifty percent of the female patients present with ovarian metastases. The histologic hallmark of this entity is the presence of clusters of goblet cells in the lamina propria or submucosa stain for various neuroendocrine markers, though the intensity is often patchy. Atypia is usually minimal, but carcinomatous growth patterns may be seen. These may be of signet ring cell type or poorly differentiated adenocarcinoma. Recently molecular studies have shown these tumors to lack the signatures of adenocarcinoma but they have some changes similar to that of ileal carcinoids (allelic loss of chromosome 11q, 16q and 18q). The natural history of GCC is intermediate between carcinoids and adenocarcinomas of the appendix. The 5-year overall survival is 76%. The most important prognostic factor is the stage of disease. Appendectomy and right hemicolectomy are the main modalities of treatment, followed by adjuvant chemotherapy in select cases.


2. ¼ö¼ú·Î Ä¡·áÇÑ Áõ·Ê


Mixed exo- and endocrine carcinoma (G3) (Specify : amphicrine carcinoma)
1. Name of Procedure: Subtotal gastrectomy
2. Site of Tumor: Stomach (Body and posterior wall)
3. Diagnosis: Mixed exo-and endoccrine carcinoma (G3) (specify: Amphicrine carcinoma)
4. WHO classification(2010): Mixed exo- and endocrine carcinoma (Specify : amphicrine)
5. Multiplicity: Single
6. Size: 2.4x1.7 cm
7. Extent: Proper Muscle (pT2)
8. Grading: Mitotic Count(/10HPF): > 20 , Ki-67 labeling index: G3>20%
9. Immunohistochemical Stains: Synaptophysin: Positive, Chromogranin A: Positive
10. Lymphovascular invasion: Present
11. Perineural invasion: Present
12. Lymph node metastasis: Number of positive nodes/Total number of nodes(0/30)
13. Resection Margins: Negative


3. ³»½Ã°æÀ¸·Î Ä¡·áÇÑ Áõ·Ê


Stomach, mid body, anterior wall, endoscopic mucosal resection:
Adenocarcinoid (amphicrine tumor)
1. Name of Procedure: EMR
2. Site of Tumor: Stomach (Body)
3. Diagnosis: Mixed exo- and endocrine tumor
4. WHO classification(2010): Mixed exo- and endocrine carcinoma, grade 2 (specify: adenocarcinoid)
5. Multiplicity: Single
6. Size: 0.4x0.4 cm
7. Extent: Mucosa and submucosa
8. Grading: Mitotic count(/10 HPF): 0-1, Ki-67 labeling index: G2 3-20% (Positive in about 5% of tumor cells)
9. Immunohistochemical Stains: a. Synaptophysin: Positive, b. Chromogranin A: Positive
10. Lymphovascular invasion: Not identified
11. Perineural invasion: Not identified
12. Lymph node metastasis: not evaluated
13. Resection Margins: Negative, safety margin: 50§­ (deep)


[Cases]

À§¾Ï 604
Stomach, subtotal gastrectomy: Advanced gastric carcinoma
1. Location : lower third, Center at antrum and lesser curvature
2. Gross type : Borrmann type 2
3. Histologic type : tubular adenocarcinoma, moderately differentiated with focal neuroendocrine differentiation
4. Histologic type by Lauren : intestinal
5. Size : 3.5x4.5 cm
6. Depth of invasion : penetrates subserosal connective tissue (pT3)
7. Resection margin: free from carcinoma, safety margin: proximal 4.5 cm, distal 4 cm
8. Lymph node metastasis : metastasis to 5 out of 52 regional lymph nodes (pN2) (perinodal extension: present) (5/52: "3", 2/17; "4", 1/14; "5", 1/2; "6", 0/4; "7", 0/2; "8a", 0/2; "9", 0/1; "11p", 0/2; "12a", 1/3; "4sb", 0/4; "1", 0/0; "4d", 0/1)
9. Lymphatic invasion : not identified
10. Venous invasion : not identified
11. Perineural invasion : not identified
12. Associated findings : ulceration
13. Peritoneal cytology : negative
14. AJCC stage by 7th edition: pT3 N2



© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.